🔥 M&A News 🔥

$AbbVie(ABBV.US)$ to acquire $Landos Biopharma(LABP.US)$
⇒ $137.5M deal at $20.42/sh 💰💰
⇒ strengthens portfolio in inflammatory & autoimmune diseases
⇒ Adds lead asset NX-13 (Ph2 trial UC)

$Nuvation Bio(NUVB.US)$ to acquire AnHeart Therapeutics
⇒ all-stock transaction
⇒ transforms NUVB into late-stage global oncology company
⇒ Includes taletrectinib with ongoing trials NSCLC)

$Novo-Nordisk A/S(NVO.US)$ to acquire Cardior Pharmaceuticals
⇒ 1.025 B euros deal 💰💰
⇒ strengthens pipeline in CV disease
⇒ includes lead asset CDR132L (Ph2 trial heartfailure)